<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080803</url>
  </required_header>
  <id_info>
    <org_study_id>ESASO</org_study_id>
    <nct_id>NCT05080803</nct_id>
  </id_info>
  <brief_title>Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome</brief_title>
  <official_title>Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European School of Advanced Studies in Ophthalmology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European School of Advanced Studies in Ophthalmology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective multi-center observational study on functional and morphological outcome of&#xD;
      initial therapy for DME according to ESASO Morphologic Classification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ESASO morphologic classification of diabetic macular edema defines four stages of&#xD;
      progression of the disease: early, advanced, chronic and atrophic maculopathy.&#xD;
&#xD;
      This grading is generated by the analysis of seven biomarkers that fully describe the level&#xD;
      of retinal damage. Aim of this classification is to be a valid method for a comprehensive&#xD;
      description of DME in scientific studies or clinical practice.&#xD;
&#xD;
      Given the recent publication of ESASO Classification, there aren't observations on the real&#xD;
      relevance of grading DME on therapeutic outcome.&#xD;
&#xD;
      This retrospective study wants to give a preliminary answer to this important issue.&#xD;
&#xD;
      As a corollary outcome, this study will also evaluate the concordance of grading among&#xD;
      participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Functional and morphological improvement in DME after initial therapeutic loading phase, according to ESASO stage of progression of the disease.</measure>
    <time_frame>Four months</time_frame>
    <description>Visual acuity and morphological (OCT) stage of the disease (as described in ESASO DME classification) will be evaluated at time 0 and four months after the first injection of intravitreal dexamethasone or one month after the loading phase (3 monthly injections) with anti-VEGF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of ESASO DME staging classification</measure>
    <time_frame>3 months</time_frame>
    <description>After preliminary instruction on ESASO Staging system of DME, participating centers will evaluate the stage of DME at time 0 of every eye retrospectically selected to participate to the study. This staging will be than validated by the Coordinating Center, and the total concordance of staging (K index) will be used to validate the Classification</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Early DME</arm_group_label>
    <description>Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced DME</arm_group_label>
    <description>Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe DME</arm_group_label>
    <description>Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrophic diabetic maculopathy</arm_group_label>
    <description>Functional results after the loading therapeutic phase. The efficacy of different drugs (bevacizumab, ranibizumab, aflibercept, desamethazone) will be analyzed separately</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone</intervention_name>
    <description>intravitreal administration</description>
    <arm_group_label>Advanced DME</arm_group_label>
    <arm_group_label>Atrophic diabetic maculopathy</arm_group_label>
    <arm_group_label>Early DME</arm_group_label>
    <arm_group_label>Severe DME</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        B. Major Eligibility Criteria&#xD;
&#xD;
          1. Age ≥ 50 years&#xD;
&#xD;
          2. Type 1 or type 2 diabetes&#xD;
&#xD;
          3. No history/presence of any other ocular/macular pathology&#xD;
&#xD;
          4. No history of IV/laser treatment in the past 8 months&#xD;
&#xD;
          5. No history of cataract or other ocular surgery in the past 6 months&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria. Eligible eyes at the retrospective review&#xD;
&#xD;
          1. Any stage of DME treated with a loading dose of 3 anti-VEGF (any type) or 1 IV&#xD;
             dexamethasone (STEP 1).&#xD;
&#xD;
          2. OCT scans and retinal maps (radial/raster lines) at baseline (max 1 month before&#xD;
             injection) and at one month (max 6 weeks) after the third anti-VEGF or at 3 months&#xD;
             (max 16 weeks) after IV steroid injection (STEP 2).&#xD;
&#xD;
          3. VA at the time of both OCT examinations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Past ocular surgery of any kind (except for cataract surgery) or ocular pathologies&#xD;
             other than diabetic retinopathy.&#xD;
&#xD;
          2. Macular edema considered to be due to a cause other than diabetic macular edema.&#xD;
&#xD;
          3. OCT examination suggesting that vitreoretinal interface abnormalities (e.g., a taut&#xD;
             posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema.&#xD;
             In the case of ERM, an OCT scan must be sent to the Coordinating Center for approval.&#xD;
&#xD;
          4. Any ocular pathology or ocular condition other than diabetes that in the opinion of&#xD;
             the investigator might affect macular edema.&#xD;
&#xD;
          5. History of any therapy (anti-VEGF treatment, focal/grid macular photocoagulation,&#xD;
             intravitreous or peribulbar corticosteroids) for DME or diabetic retinopathy in the&#xD;
             past 8 months.&#xD;
&#xD;
          6. History of YAG capsulotomy performed within two months before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Giacomo Panozzo, MD</last_name>
    <phone>045502390</phone>
    <email>g.panozzo@iol.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giacomo Panozzo</last_name>
    <phone>045502390</phone>
    <email>g.panozzo@iol.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ESASO Scientific Projects</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6901</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giacomo A Panozzo, MD</last_name>
      <phone>+393483365239</phone>
      <email>g.panozzo@iol.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Panozzo G, Cicinelli MV, Augustin AJ, Battaglia Parodi M, Cunha-Vaz J, Guarnaccia G, Kodjikian L, Jampol LM, Jünemann A, Lanzetta P, Löwenstein A, Midena E, Navarro R, Querques G, Ricci F, Schmidt-Erfurth U, Silva RMD, Sivaprasad S, Varano M, Virgili G, Bandello F. An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: The European School for Advanced Studies in Ophthalmology classification. Eur J Ophthalmol. 2020 Jan;30(1):8-18. doi: 10.1177/1120672119880394. Epub 2019 Nov 12.</citation>
    <PMID>31718271</PMID>
  </reference>
  <reference>
    <citation>Panozzo G, Mura GD, Franzolin E, Giannarelli D, Albano V, Alessio G, Arrigo A, Casati S, Cassottana P, Contardi C, D'Aloisio R, Fasce F, Gusson E, Marchini G, Mastropasqua L, Niccolò M, Palmisano C, Pastore MR, Saviano S, Tognetto D, Bandello F. Early DMO: a predictor of poor outcomes following cataract surgery in diabetic patients. The DICAT-II study. Eye (Lond). 2021 Aug 3. doi: 10.1038/s41433-021-01718-4. [Epub ahead of print]</citation>
    <PMID>34345028</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic macular edema</keyword>
  <keyword>ESASO Classification</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

